Jeanette Bjorkquist
ASSEMBLY BIOSCIENCESAbout Jeanette Bjorkquist
Jeanette M. Bjorkquist is Vice President, Finance and serves as Assembly Biosciences’ Principal Financial Officer and Principal Accounting Officer; she was appointed PFO on June 5, 2025 and certified the Company’s Q3 2025 Form 10‑Q under SOX Sections 302 and 906 . She joined Assembly in April 2019 and has progressed through accounting and treasury leadership roles, becoming VP, Finance in June 2025 at age 38 . Company performance context: Assembly’s total shareholder return improved to 160.34 in 2024, up from 63.08 in 2023 and 21.49 in 2022; the company reported a net loss of $40.2 million in 2024 . Collaboration revenue for the nine months ended September 30, 2025 increased 41% year over year to $29.8 million, driven by higher activity and funding under the Gilead collaboration .
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total Shareholder Return (Index) | 21.49 | 63.08 | 160.34 |
| Net Loss ($USD Thousands) | $(93,092) | $(61,228) | $(40,177) |
| Metric | Nine Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2025 | YoY Change |
|---|---|---|---|
| Collaboration Revenue from Related Party ($USD Thousands) | $21,163 | $29,834 | +41% |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Assembly Biosciences | VP, Finance (Principal Financial Officer and Principal Accounting Officer) | Jun 2025–present | Principal financial and accounting officer; signed SOX certifications on Q3 2025 10‑Q . |
| Assembly Biosciences | Executive Director, Accounting & Treasury | Feb 2023–Jun 2025 | Led accounting and treasury; progression to PFO reflects increasing responsibility . |
| Assembly Biosciences | Senior Director, Accounting & Treasury | Apr 2021–Feb 2023 | Oversaw accounting/treasury functions supporting disclosure controls . |
| Assembly Biosciences | Director, Controller | Aug 2020–Apr 2021 | Controller responsibilities; foundation for principal accounting leadership . |
| Assembly Biosciences | Associate Director, Accounting & Reporting | Apr 2019–Aug 2020 | Managed accounting/reporting processes early in tenure . |
External Roles
No external directorships or outside roles disclosed for Ms. Bjorkquist in available filings. If present, they would be reflected in 8‑K 5.02 or proxy biographies; none were reported .
Fixed Compensation
Not disclosed. Ms. Bjorkquist was not a named executive officer (NEO) in the 2025 proxy; therefore base salary, target bonus, and actual bonus figures are not individually reported .
Performance Compensation
Not disclosed for Ms. Bjorkquist. Assembly’s executive compensation framework emphasizes pay-for-performance with annual cash bonuses tied to weighted corporate objectives and individual goals (for non-CEO employees), and equity awards with multi-year vesting; in 2024 corporate goals were achieved at 129.25% across development, research, finance/corporate development, and organizational retention, but individual payouts disclosed only for NEOs .
Equity Ownership & Alignment
- Individual beneficial ownership for Ms. Bjorkquist is not disclosed in the Security Ownership table (covers >5% holders, directors, and NEOs) .
- Company policies prohibit hedging or pledging of company stock and provide clawback provisions; options repricing is prohibited without shareholder approval .
- Minimum one-year vesting for employee grants and double-trigger change-in-control treatment under the equity plan; performance-based RSUs planned for broad-based retention in 2025 with vesting contingent on initiation of a Phase 2 or Phase 3 by end of 2027 (50% on milestone/first anniversary, 50% one year later) .
Employment Terms
- Appointment: On June 5, 2025, the Board appointed Ms. Bjorkquist as Principal Financial Officer alongside her role as Principal Accounting Officer; she succeeded the CEO in the PFO function .
- Related party and arrangements: No arrangements or understandings led to her appointment; no family relationships; no transactions requiring Item 404(a) disclosure .
- Change-in-control economics: Under the Amended and Restated 2018 Stock Incentive Plan, if awards are not assumed/replaced in a corporate transaction, time-based awards vest, performance awards vest per award agreements or at target (prorated/higher of actual), and the Company may cash out options/SARs and vested awards; the plan forbids repricing without shareholder approval .
- Clawback: Company maintains clawback policy applicable to executives .
Investment Implications
- Elevation to principal financial officer concentrates financial reporting accountability with a career accounting leader who is actively certifying controls and disclosures, a positive governance signal for reliability of reporting .
- Equity alignment is supported by company-wide policies (no hedging/pledging; minimum vesting; clawbacks); any future PSUs granted under the 2025 supplemental retention program will vest only on clinical milestones, creating potential vest-driven supply around certification dates but tying executive upside to value-creating events .
- Lack of disclosed individual compensation and holdings limits precision on personal selling pressure; however, prohibition of pledging and double-trigger CIC treatment reduces immediate misalignment risks; monitor future proxies and Form 4s for grant/vesting cadence and any sales by Ms. Bjorkquist .
- Company performance trends (TSR up in 2024; collaboration revenue up 41% YTD 2025) indicate improving fundamentals under current leadership; as PFO, her execution on controls amid increased collaboration activity is relevant to forecasting, capital markets readiness, and risk management for investors .